Please assess the completion status of the following clinical trial:

Trial Title: Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~A patient will be eligible for inclusion only if all of the following criteria are fulfilled:~1. Recurrent platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer (platinum sensitivity defined as no recurrence within 6 months of last receipt of platinum/chemotherapy).~2. High-grade serious or high-grade endometrioid histology.~3. Patient consents to perform HRD test.~   * Patients with known BRCA status: BRCA positive patients must submit the tissue for HRD test, though these patients need not to wait for HRD test results and can be randomized in HRD positive stratum.~  * If tumor tissue is not sufficient to perform HRD test: these patients shall be randomized in HRD negative stratum as HRD unknown.~4. Prior line of therapy: Patients must have received platinum-containing therapy for primary disease.~   * No limits on number of platinum-based therapies. Population of patients who has previously received ≥ 3 lines of therapy for relapsed disease will be capped at 40%.~  * Up to one non-platinum-based line of therapy in recurrent setting.~  * Patients who are treated with bevacizumab just prior to entering in the trial must not have progressed under or within 3 months after bevacizumab.~  * Patients may have participated in a PARP inhibitor trial as first-line maintenance therapy and have not progressed within 3 months after PARP/placebo. Patients who received PARP inhibitor after relapse (definitive or maintenance therapy) are not eligible.~5. Target group: Age 18+~6. Histological confirmed ovarian, fallopian tube or peritoneal cancers~7. Patients must give informed consent~8. Patients may have undergone primary or interval debulking surgery~9. Patients may have received bevacizumab though no other prior use of anti-angiogenic therapy~10. Patients may have received a PARP inhibitor as first-line maintenance therapy.~11. Patients must have disease that is measurable according to RECIST or assessable according to the GCIG criteria~12. The patient agrees to complete PROs (QoL questionnaire) during study treatment AND at one additional time point 8 weeks following progression of disease~13. ECOG performance status 0-2~14. Adequate organ function~    * Absolute neutrophil count (ANC) ≥1,5 x 109/L~   * Platelets \>100 x 109/L~   * Hemoglobin ≥ 9g/dl~   * Serum creatinine ≤1.5x upper limit of normal (ULN) or calculated creatinine clearance ≥50mL/min using Cockcroft-Gault formula~   * Total bilirubin ≤1.5x ULN~   * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5x ULN unless liver metastases are present, in which case they must be ≤5x ULN.~15. Able to take oral medications~16. Life expectancy of at least 12 weeks~17. Patients must fulfill all inclusions criteria and according to investigator fit to receive niraparib and/or bevacizumab.~18. Women of childbearing potential must use adequate birth control for the duration of study participation~Exclusion Criteria:~A patient will not be eligible for inclusion if any of the following criteria are fulfilled:~1. Ovarian sarcomas, small cell carcinoma with neuroendocrine differentiation, non-epithelial cancers and cancer types not mentioned in the inclusion criteria~2. Concurrent cancer therapy~3. Concurrent treatment with an investigational agent or participation in another clinical trial~4. Major injuries or surgery within the past 21 days prior to start of study treatment with incomplete wound healing and/or planned surgery during the on-treatment study period~5. Previous malignant disease: patients are not eligible for the study if diagnosis, detection or treatment of invasive cancer (other than ovarian cancer; with the exception of basal or squamous cell carcinoma of the skin that was definitively treated) was detected within 2 years prior to randomization~6. Active infections or other serious underlying significant medical illness, abnormal laboratory finding or psychiatric illness/social situation that would, in the Investigator's judgment, makes the patient inappropriate for this study~7. Gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug~8. History of bowel obstruction, including sub-occlusive disease, related to the underlying disease and history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess. Evidence of recto-sigmoid involvement by pelvic examination or bowel involvement on CT scan or clinical symptoms of bowel obstruction~9. Known contraindications to PARP inhibitors or VEGF directed therapy~10. Known uncontrolled hypersensitivity to the investigational drugs~11. History of major thromboembolic event defined as:~    * Uncontrolled pulmonary embolism (PE)~   * Deep venous thrombosis (DVT)~   * Other related conditions, though patients with stable therapeutic anticoagulation for more than three months prior randomization are eligible for this study. This also apply to PE \& DVT.~12. History of a cerebral vascular accident, transient ischemic attack or subarachnoid hemorrhage within the past 3 months~13. History of clinically significant hemorrhage in the past 3 months~14. Uncontrolled and/or symptomatic CNS metastasis or leptomeningeal carcinomatosis (Dexamethasone/prednisone therapy will be allowed if administered as stable dose for at least one month prior randomization)~15. Significant cardiovascular diseases, including uncontrolled hypertension, clinically relevant cardiac arrhythmia, unstable angina or myocardial infarction within 6 months prior to randomization, congestive heart failure \> NYHA III, severe peripheral vascular disease, QT prolongation \>470 msec ,clinically significant pericardial effusion~16. Pregnancy or breastfeeding. Patients with preserved reproductive capacity, unwilling to use a medically acceptable method of contraception for the duration of the trial and for 3 months afterwards.~17. Radiographic evidence of cavitation or necrotic tumors with invasion of adjacent major blood vessels~18. Active or chronic hepatitis C and/or B infection~19. Persistence of clinically relevant therapy related toxicity from previous chemotherapy~20. Proteinuria as demonstrated by: (a) urine protein: creatinine (UPC) ratio \>/= 1.0 at screening OR (b) urine dipstick for proteinuria \>/=2+ (patients discovered to have \>/=2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hr urine collection and must demonstrate \</=1g of protein in24 hours to be eligible~21. Patients must not have any known history of MDS~22. Patients must not have known persistent (\> 4 weeks) ≥ Grade 2 hematological toxicity from prior cancer therapy~23. Patients must not have known ≥ Grade 3 thrombocytopenia or anemia with the last chemotherapy regimen.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Niraparib monotherapy (Type: EXPERIMENTAL): Niraparib mono therapy until progression
- Niraparib-bevacizumab combination (Type: EXPERIMENTAL): Niraparib-bevacizumab combination therapy until progression

Based on this trial design, predict the completion outcome and termination type (if applicable).